Eliquis Lawsuit Information

The first Eliquis lawsuit was filed in the Southern District of New York in July 2015, by the wife of Donald Herschell, who was prescribed Eliquis in 2014 to treat his irregular heartbeat. Just two months after beginning treatment with Eliquis, Herschell suffered gastrointestinal bleeding that doctors were unable to control, and died in the hospital that same day. According to allegations raised in the Herschells’ lawsuit, Pfizer and Bristol-Myers Squibb used incompetent researchers in the ARISTOTLE study that the FDA based its Eliquis approval on, misled the public by failing to disclose the study errors, and failed to adequately warn Eliquis users about the risks associated with using a blood thinner that has no antidote.

At least two other Eliquis lawsuits have been brought against the makers of the controversial blood thinner, both pursuing compensation for costly medical bills, lost wages, pain and suffering, loss of enjoyment of life, and punitive damages. As more and more atrial fibrillation patients become aware of the potential for the blockbuster blood thinner to cause uncontrollable bleeding and other life-threatening side effects in users, additional Eliquis lawsuits are expected to be brought against Pfizer and Bristol-Myers in the future.

“unlike warfarin, Eliquis has no approved antidote, which means doctors are unable to reverse the blood-thinning effects of the medication in the event of a serious bleeding complication.”

Reported Side Effects of Eliquis

Patients taking Eliquis to reduce their risk of stroke and blood clots may be at risk for the following side effects:

  • Internal bleeding requiring hospitalization
  • Rectal bleeding
  • Kidney bleeding
  • Gastrointestinal (GI) bleeding
  • Cerebral hemorrhages
  • Death
Call To Speak With a Representative    877-920-4111

What is Eliquis?

Eliquis is a next-generation blood thinner manufactured and marketed by Pfizer and Bristol-Myers Squibb, commonly prescribed to patients diagnosed with a heart rhythm problem called atrial fibrillation, to reduce their risk of stroke and dangerous blood clots. Eliquis works by thinning the blood, which decreases the likelihood of blood clots forming, thereby reducing the risk of clots traveling to the brain and causing a stroke. Like Pradaxa and Xarelto, two other popular blood thinners currently on the market, Eliquis was developed as an alternative to warfarin, and aimed to exceed the older anticoagulant’s effectiveness, while doing away with the need for frequent blood tests. However, unlike warfarin, Eliquis has no approved antidote, which means doctors are unable to reverse the blood-thinning effects of the medication in the event of a serious bleeding complication.

Reasons to Bring About Eliquis Litigation

Eliquis lawsuits brought against Pfizer and Bristol-Myers Squibb include the following allegations:

  • Failure to warn – Manufacturers failed to adequately warn about the risks associated with a blood thinner that has no reversal agent.
  • Fraud – Manufacturers fraudulently concealed adverse events in its Eliquis clinical trial in China.
  • Negligence – Manufacturers were negligent in their design, research, manufacturing and marketing of Eliquis.
  • False claims – Manufacturers misrepresented the safety of Eliquis in direct-to-consumer advertising.
  • Compensation – Patients harmed by alleged side effects of Eliquis may be entitled to compensation for emotional distress, medical expenses, lost wages and other economic damages.

History of Eliquis

Since Eliquis first garnered approval from the FDA in 2013, the blood thinner has been marketed as a superior alternative to warfarin, an older-generation anticoagulant drug that has been on the market in the United States for more than 50 years. According to Pfizer and Bristol-Myers, Eliquis is safer and more convenient than warfarin, because the new-generation blood thinner resulted in fewer deaths in the ARISTOTLE clinical trial, and doesn’t require regular blood monitoring during treatment. However, serious concerns have been raised recently about the safety of Eliquis, after it was discovered that the ARISTOTLE study, which the FDA based its approval of Eliquis on, was heavily flawed. According to reports, study flaws included inaccurate and missing data, failure to report deaths and other adverse events, patients receiving incorrect medications, and patients receiving incorrect dosages of medications. The FDA twice delayed its approval of Eliquis while waiting for the results of the ARISTOTLE study, which compared the safety and effectiveness of Eliquis to that of warfarin, and FDA reviewers and medical scholars have since criticized the results of the ARISTOTLE study.